Clone:
REA805
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC
Alternative names:
HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5

Extended validation for HLA-DR Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA805
L243++
LN3-
AC122++
Tü36-
REA332-
Tü39-
Cells were incubated with an excess of purified unconjugated HLA-DR (REA805) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for Anti-HLA-DR. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-HLA-DR antibodies and plotted against the side scatter. As a control, Anti-HLA-DR antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for Anti-HLA-DR. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-HLA-DR antibodies and plotted against the side scatter. As a control, Anti-HLA-DR antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for Anti-HLA-DR. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-HLA-DR antibodies and plotted against the side scatter. As a control, Anti-HLA-DR antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for Anti-HLA-DR. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-HLA-DR antibodies and plotted against the side scatter. As a control, Anti-HLA-DR antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for Anti-HLA-DR. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-HLA-DR antibodies and plotted against the side scatter. As a control, Anti-HLA-DR antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for Anti-HLA-DR. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-HLA-DR antibodies and plotted against the side scatter. As a control, Anti-HLA-DR antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for Anti-HLA-DR. Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-HLA-DR antibodies and plotted against the side scatter. As a control, Anti-HLA-DR antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using HLA-DR (REA805). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using HLA-DR (REA805). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using HLA-DR (REA805). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for HLA-DR Antibody, anti-human, REAfinity™

Overview

Clone REA805 recognizes the human major histocompatibility (MHC) class II antigen HLA-DR, a heterodimeric cell surface glycoprotein belonging to the Ig superfamiliy. HLA-DR is constitutively expressed on professional antigen-presenting cells like dendritic cells, B cells, and monocytes/macrophages. Its expression is further up-regulated upon activation. On T cells, natural killer (NK) cells, hematopoietic precursor cells, and some epithelial cells the expression of HLA-DR is induced by cell activation.
Additional information: Clone REA805 displays negligible binding to Fc receptors.

Alternative names

HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5

Detailed product information

Technical specifications

CloneREA805
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hosthuman cell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman, non-human primate
Cross-reactivity
cynomolgus monkey (
Macaca fascicularis
)
,
african green monkey (
Chlorocebus aethiops
)
, baboon,
chimpanzee (
Pan troglodytes
)
,
common marmoset (
Callithrix jacchus
)
,
cotton-top tamarin (
Saguinus oedipus
)
,
pigtail monkey (
Macaca nemestrina
)
AntigenHLA-DR
Alternative names of antigenHLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5
Molecular mass of antigen [kDa]27-33
Distribution of antigenB cells, dendritic cells, macrophages, monocytes
Entrez Gene ID3123, 3122, 3127, 3126, 3125
RRIDAB_2652156, AB_2652157, AB_2652158, AB_2652159, AB_2652160, AB_2652161, AB_2652162, AB_2652163, AB_2652164, AB_2652165, AB_2652166, AB_2652167, AB_2652168, AB_2652169, AB_2652170, AB_2652171, AB_2652172, AB_2652173, AB_2652174, AB_2801880, AB_2652155

Resources for HLA-DR Antibody, anti-human, REAfinity™

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for HLA-DR Antibody, anti-human, REAfinity™

Publications

  1. Brodsky, F. M. (1984) A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes. Immunogenetics 19(3): 179-194
  2. Edwards, J. A. et al. (1986) Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression. J Immunol 137(2): 490-497

Related products for
HLA-DR Antibody, anti-human, REAfinity™

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?